Wang Zhuoqun, Song Yunping, A Geru, Li Yongle
Department of Cardiology, Tianjin Medical University General Hospital.
Int Heart J. 2019 Sep 27;60(5):1077-1082. doi: 10.1536/ihj.18-725. Epub 2019 Aug 23.
Patients with ST-segment elevation myocardial infarction (STEMI) who are treated by primary percutaneous coronary intervention (PPCI) have an increased risk of developing contrast-induced nephropathy (CIN) when compared with patients undergoing elective percutaneous coronary intervention (PCI). However, CIN prevention measures are less frequently applied in PPCI than in elective PCI. At present, no preventive strategy has been recommended by the current guidelines for patients with STEMI undergoing PPCI.Published research was scanned by formal searches of electronic databases (PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials) from 1966 to July 2018. Internet-based sources of information on the results of clinical trials in cardiology were also searched.A total of three randomized trials involving 924 patients were included in the present meta-analysis, of whom 462 received hydration with isotonic saline (hydration group) and 462 received no hydration (control group). Periprocedural hydration with isotonic saline was associated with a significant decrease in the rate of CIN (16.9% in the hydration group versus 26.4% in the control group; summary risk ratio: 0.64, 95% confidence interval: 0.50-0.82, P = 0.0005). There was no difference in the rate of postprocedural hemodialysis or death between the groups.Intravenous saline hydration during PPCI reduced the risk of CIN without significantly altering the rate of requirement for renal replacement therapy or mortality.
与接受择期经皮冠状动脉介入治疗(PCI)的患者相比,接受直接经皮冠状动脉介入治疗(PPCI)的ST段抬高型心肌梗死(STEMI)患者发生造影剂肾病(CIN)的风险增加。然而,与择期PCI相比,PPCI中CIN预防措施的应用频率较低。目前,现行指南尚未针对接受PPCI的STEMI患者推荐预防策略。
通过对电子数据库(PubMed、EMBASE和Cochrane对照试验中央注册库)进行1966年至2018年7月的正式检索,对已发表的研究进行了筛选。还检索了基于互联网的心脏病学临床试验结果信息来源。
本荟萃分析共纳入了三项涉及924例患者的随机试验,其中462例接受等渗盐水水化治疗(水化组),462例未接受水化治疗(对照组)。围手术期使用等渗盐水水化与CIN发生率显著降低相关(水化组为16.9%,对照组为26.4%;汇总风险比:0.64,95%置信区间:0.50 - 0.82,P = 0.0005)。两组术后血液透析率或死亡率无差异。
PPCI期间静脉输注盐水水化可降低CIN风险,且不会显著改变肾脏替代治疗需求率或死亡率。